Multiple mechanisms underlie resistance of leukemia cells to Apo2 Ligand/TRAIL

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Molecular Cancer Therapeutics

• Publication date

  2006-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1535-7163.MCT-06-0050PMID 16891471
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Receptor-selective Mutants of Apoptosis-inducing Ligand 2/Tumor Necrosis Factor-related Apoptosis-inducing Ligand Reveal a Greater Contribution of Death Receptor (DR) 5 than DR4 to Apoptosis Signaling*

  2005cited by this paper
• Sensitivity of adult T‐cell leukaemia lymphoma cells to tumour necrosis factor‐related apoptosis‐inducing ligand

  2005cited by this paper
• Targeting death receptors in cancer with Apo2L/TRAIL.

  2004cited by this paper
• Deficient Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Death Receptor Transport to the Cell Surface in Human Colon Cancer Cells Selected for Resistance to TRAIL-induced Apoptosis*

  2004cited by this paper
• Emerging non‐apoptotic functions of tumor necrosis factor‐related apoptosis‐inducing ligand (TRAIL)/Apo2L

  2004cited by this paper
• Differential regulation of the TRAIL death receptors DR4 and DR5 by the signal recognition particle.

  2004cited by this paper
• Constitutively active Akt1 protects HL60 leukemia cells from TRAIL-induced apoptosis through a mechanism involving NF-κB activation and cFLIPL up-regulation

  2003cited by this paper
• Silencing of death receptor and caspase-8 expression in small cell lung carcinoma cell lines and tumors by DNA methylation

  2003cited by this paper
• Apo2L/TRAIL and its death and decoy receptors

  2003cited by this paper
• Synthetic triterpenoids activate a pathway for apoptosis in AML cells involving downregulation of FLIP and sensitization to TRAIL

  2003cited by this paper
• Mutation analysis and mRNA expression of trail‐receptors in human breast cancer

  2002cited by this paper
• Tumor-cell resistance to death receptor–induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax

  2002cited by this paper
• Targeting death and decoy receptors of the tumour-necrosis factor superfamily

  2002cited by this paper
• Caspase‐10 is recruited to and activated at the native TRAIL and CD95 death‐inducing signalling complexes in a FADD‐dependent manner but can not functionally substitute caspase‐8

  2002cited by this paper
• A Novel Single Amino Acid Deletion Caspase-8 Mutant in Cancer Cells That Lost Proapoptotic Activity*

  2002cited by this paper
• Ectopic Expression of Bcl-2 and Bcl-xL Inhibits Apoptosis Induced by TNF-Related Apoptosis-Inducing Ligand (TRAIL) Through Suppression of Caspases-8, 7, and 3 and BID Cleavage in Human Acute Myelogenous Leukemia Cell Line HL-60

  2002cited by this paper
• Death Receptor Recruitment of Endogenous Caspase-10 and Apoptosis Initiation in the Absence of Caspase-8*

  2001cited by this paper
• Isotype-Dependent Inhibition of Tumor Growth In Vivo by Monoclonal Antibodies to Death Receptor 4

  2001cited by this paper
• TRAIL/Apo-2L: mechanisms and clinical applications in cancer.

  2001cited by this paper
• In vitro susceptibility to TRAIL-induced apoptosis of acute leukemia cells in the context of TRAIL receptor gene expression and constitutive NF-κB activity

  2001cited by this paper
• Signaling events triggered by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL): caspase-8 is required for TRAIL-induced apoptosis.

  2001cited by this paper
• Bcl-2 over-expression and activation of protein kinase C suppress the Trail-induced apoptosis in Jurkat T cells

  2001cited by this paper
• Somatic mutations of TRAIL-receptor 1 and TRAIL-receptor 2 genes in non-Hodgkin's lymphoma

  2001cited by this paper
• Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions

  2001cited by this paper
• Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer

  2001cited by this paper
• Allelic imbalance on chromosome 2q and alterations of the caspase 8 gene in neuroblastoma

  2001cited by this paper
• Resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression.

  2001cited by this paper
• Aggressive childhood neuroblastomas do not express caspase-8: an important component of programmed cell death

  2001cited by this paper
• Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5.

  2000influential reference
• Human brain-cell death induced by tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL)

  2000cited by this paper
• TRAIL receptor-2 signals apoptosis through FADD and caspase-8

  2000cited by this paper
• The Tumor Necrosis Factor-related Apoptosis-inducing Ligand Receptors TRAIL-R1 and TRAIL-R2 Have Distinct Cross-linking Requirements for Initiation of Apoptosis and Are Non-redundant in JNK Activation*

  2000cited by this paper
• Homozygous deletion of the death receptor DR4 gene in a nasopharyngeal cancer cell line is associated with TRAIL resistance.

  2000cited by this paper
• Resistance to TRAIL-induced apoptosis in primitive neuroectodermal brain tumor cells correlates with a loss of caspase-8 expression

  2000cited by this paper
• FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2.

  2000cited by this paper
• Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand

  2000cited by this paper
• Expression of tumour necrosis factor (TNF)‐related apoptosis‐inducing ligand (TRAIL) receptors and sensitivity to TRAIL‐induced apoptosis in primary B‐cell acute lymphoblastic leukaemia cells

  2000cited by this paper
• Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN

  2000cited by this paper
• Type I Interferons (IFNs) Regulate Tumor Necrosis Factor–related Apoptosis-inducing Ligand (TRAIL) Expression on Human T Cells: A Novel Mechanism for the Antitumor Effects of  Type I IFNs

  1999cited by this paper
• Caspase Cleaved BID Targets Mitochondria and Is Required for Cytochrome c Release, while BCL-XL Prevents This Release but Not Tumor Necrosis Factor-R1/Fas Death*

  1999cited by this paper
• Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo

  1999cited by this paper
• IAPs block apoptotic events induced by caspase‐8 and cytochrome c by direct inhibition of distinct caspases

  1998cited by this paper
• Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL*

  1998cited by this paper
• Death receptors: signaling and modulation.

  1998cited by this paper
• Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis.

  1998cited by this paper
• IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs.

  1998cited by this paper
• Inhibition of death receptor signals by cellular FLIP

  1997cited by this paper
• An antagonist decoy receptor and a death domain-containing receptor for TRAIL.

  1997cited by this paper
• Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death.

  1996cited by this paper
• Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family*

  1996cited by this paper
• Identification and characterization of a new member of the TNF family that induces apoptosis.

  1995cited by this paper

• Fisetin reduces the resistance of MOLT-4 and K562 cells to TRAIL-induced apoptosis through upregulation of TRAIL receptors

  2024influential citation
• Acquired Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Resistance of Human Colorectal Cancer Cells Is Linked to Histone Acetylation and Is Synergistically Ameliorated by Combination with HDAC Inhibitors

  2024cites this paper
• Pro-Inflammatory Activation Suppresses TRAIL-induced Apoptosis of Acute Myeloid Leukemia Cells

  2024influential citation
• Nimesulide, a COX-2 inhibitor, sensitizes pancreatic cancer cells to TRAIL-induced apoptosis by promoting DR5 clustering †

  2023cites this paper
• Myeloid Differentiation Increases Resistance of Leukemic Cells to TRAIL-Induced Death by Reducing the Expression of DR4 and DR5 Receptors

  2023cites this paper
• Reversible Increase in Resistance of A-431 Carcinoma Cells to TRAIL-Induced Apoptosis in Confluent Cultures Corresponds to a Decrease in Expression of DR4 and DR5 Receptors

  2023cites this paper
• The Increase in the Drug Resistance of Acute Myeloid Leukemia THP-1 Cells in High-Density Cell Culture Is Associated with Inflammatory-like Activation and Anti-Apoptotic Bcl-2 Proteins

  2022cites this paper
• Macrophage-like THP-1 Cells Derived from High-Density Cell Culture Are Resistant to TRAIL-Induced Cell Death via Down-Regulation of Death-Receptors DR4 and DR5

  2022cites this paper
• Curcumin augments therapeutic efficacy of TRAIL-based immunotoxins in leukemia

  2020cites this paper
• Proteomic analysis of soluble and transmembrane proteins in human lymphoma cells

  2017cites this paper
• Overcoming chemotherapy drug resistance by targeting inhibitors of apoptosis proteins (IAPs)

  2017cites this paper
• Plumbagin enhances TRAIL-induced apoptosis of human leukemic Kasumi‑1 cells through upregulation of TRAIL death receptor expression, activation of caspase-8 and inhibition of cFLIP.

  2017cites this paper
• Resistance to TRAIL Pathway-Targeted Therapeutics in Cancer

  2017cites this paper
• Overcoming Cancer Cell Resistance to Death Receptor Targeted Therapies

  2015cites this paper
• Enhanced chemotherapy efficacy by co-delivery of shABCG2 and doxorubicin with a pH-responsive charge-reversible layered graphene oxide nanocomplex.

  2015cites this paper
• α-Hispanolol sensitizes hepatocellular carcinoma cells to TRAIL-induced apoptosis via death receptor up-regulation.

  2015cites this paper
• The XIAP inhibitor Embelin enhances TRAIL-induced apoptosis in human leukemia cells by DR4 and DR5 upregulation

  2015cites this paper
• CCT 327 enhances TRAIL-induced apoptosis through the induction of death receptors and downregulation of cell survival proteins in TRAIL-resistant human leukemia cells

  2014cites this paper
• CCT327 enhances TRAIL-induced apoptosis through the induction of death receptors and downregulation of cell survival proteins in TRAIL-resistant human leukemia cells.

  2014cites this paper
• TNF superfamily proteins in the serum of patients with B-ALL--preliminary study.

  2014cites this paper
• Absence of death receptor translocation into lipid rafts in acquired TRAIL-resistant NSCLC cells.

  2013cites this paper
• Nanoarchitectured electrochemical cytosensors for selective detection of leukemia cells and quantitative evaluation of death receptor expression on cell surfaces.

  2013cites this paper
• The DeISGylase USP18 limits TRAIL-induced apoptosis through the regulation of TRAIL levels

  2013cites this paper
• Combination anticancer nanopreparations of novel proapoptotic drug, TRAIL and siRNA

  2013cites this paper
• Multi-level disruption of the extrinsic apoptotic pathway mediates resistance of leukemia cells to TNF-related apoptosis-inducing ligand (TRAIL).

  2013cites this paper
• AXL mediates TRAIL resistance in esophageal adenocarcinoma.

  2013cites this paper
• The effect of lentivirus-mediated expression of tumor necrosis factor related apoptosis-inducing ligand and shRNA against Bcl-2 on the growth of lymphoma cells

  2012cites this paper
• The Transcription Factor Wilms Tumor 1 Confers Resistance in Myeloid Leukemia Cells against the Proapoptotic Therapeutic Agent TRAIL (Tumor Necrosis Factor α-related Apoptosis-inducing Ligand) by Regulating the Antiapoptotic Protein Bcl-xL*

  2012cites this paper
• Targeted ovarian cancer treatment: the TRAILs of resistance.

  2012cites this paper
• SAHA/TRAIL combination induces detachment and anoikis of MDA-MB231 and MCF-7 breast cancer cells.

  2012cites this paper
• Synergistic TRAIL sensitizers from Barleria alluaudii and Diospyros maritima.

  2012cites this paper
• Plumbagin treatment leads to apoptosis in human K562 leukemia cells through increased ROS and elevated TRAIL receptor expression.

  2011cites this paper
• RNAi silencing of the MEKK3 gene promotes TRAIL-induced apoptosis in MCF-7 cells and suppresses the transcriptional activity of NF-κB.

  2011cites this paper
• The scavenging of superoxide radicals promotes apoptosis induced by a novel cell-permeable fusion protein, sTRAIL:FeSOD, in tumor necrosis factor-related apoptosis-inducing ligand-resistant leukemia cells

  2011cites this paper
• Redistribution of DR4 and DR5 in lipid rafts accounts for the sensitivity to TRAIL in NSCLC cells.

  2011cites this paper
• Induction of apoptosis and cell cycle arrest in renal carcinoma cells by phenethyl isothiocyanate and the mechanisms involved

  2011cites this paper
• Apoptose: to kill or not to kill.

  2011cites this paper
• Mechanism of Wogonin-mediated sensitization of HTLV-1-associated ATL cells to TRAIL-induced apoptosis

  2011cites this paper
• Targeting apoptosis in cancer cells : improving TRAIL death receptor signaling

  2011cites this paper
• Playing the DISC: turning on TRAIL death receptor-mediated apoptosis in cancer.

  2010cites this paper
• TRAILing death in cancer.

  2010cites this paper
• Predominant antitumor effects by fully human anti-TRAIL-receptor 2 (DR5) monoclonal antibodies in human glioma cells in vitro and in vivo.

  2010cites this paper
• Identification of SRP 72 as an essential regulator of TRAIL-induced apoptosis

  2010cites this paper
• Clerodane diterpenes from Casearia arguta that act as synergistic TRAIL sensitizers.

  2010cites this paper
• Improving the response to molecular targeting of the TRAIL death receptors in colon cancer cells

  2010cites this paper
• Proapoptotic DR4 and DR5 signaling in cancer cells: toward clinical translation.

  2010cites this paper
• LGP1, A histone deacetylase inhibitor analogue of FR235222, sensitizes promyelocytic leukaemia U937 cells to TRAIL-mediated apoptosis.

  2010cites this paper
• TRAIL-induced apoptosis of HL60 leukemia cells: two distinct phenotypes of acquired TRAIL resistance that are accompanied with resistance to TNFalpha but not to idarubicin and cytarabine.

  2009cites this paper
• Quercetin Sensitizes Human Leukemic Cells to TRAIL-induced Apoptosis: Involvement of DNA-PK/Akt Signal Transduction Pathway

  2009cites this paper
• A cell-based high-throughput screen to identify synergistic TRAIL sensitizers

  2009cites this paper
• Repeated Treatment with Subtoxic Doses of TRAIL Induces Resistance to Apoptosis through Its Death Receptors in MDA-MB-231 Breast Cancer Cells

  2009cites this paper
• Sensitization of human K562 leukemic cells to TRAIL-induced apoptosis by inhibiting the DNA-PKcs/Akt-mediated cell survival pathway.

  2009cites this paper
• Targeting apoptosis: preclinical and early clinical experience with mapatumumab, an agonist monoclonal antibody targeting TRAIL-R1.

  2009cites this paper
• Mouse 3T3-L1 cells acquire resistance against oxidative stress as the adipocytes differentiate via the transcription factor FoxO

  2009cites this paper
• Targeting apoptosis: preclinical and early clinical experience with mapatumumab, an agonist monoclonal antibody targeting TRAIL-R1

  2009cites this paper
• Effective gene-viral therapy of leukemia by a new fiber chimeric oncolytic adenovirus expressing TRAIL: in vitro and in vivo evaluation

  2009cites this paper
• Identification of molecular targets for selective elimination of TRAIL‐resistant leukemia cells. From spots to in vitro assays using TOP15 charts

  2009cites this paper
• Apomab: an agonist monoclonal antibody directed against Death Receptor 5/TRAIL-Receptor 2 for use in the treatment of solid tumors.

  2008cites this paper
• Therapeutic targeting of apoptosis pathways in cancer

  2008cites this paper
• Enhancement of tumor-TRAIL susceptibility by modulation of autophagy

  2008cites this paper
• A combined approach with rituximab plus anti-TRAIL-R agonistic antibodies for the treatment of haematological malignancies.

  2008cites this paper
• Tumor necrosis factor-related apoptosis-inducing ligand and the regulation of hematopoiesis

  2008cites this paper
• Apomab: An agonist monoclonal antibody directed against Death Receptor 5/TRAIL-Receptor 2 for use in the treatment of solid tumors

  2008cites this paper
• Resistance of acute myeloid leukemic cells to the triterpenoid CDDO-Imidazolide is associated with low caspase-8 and FADD levels.

  2008cites this paper
• Resistance to TRAIL-induced apoptosis caused by constitutional phosphorylation of Akt and PTEN in acute lymphoblastic leukemia cells.

  2008cites this paper
• Involvement of Protective Autophagy in TRAIL Resistance of Apoptosis-defective Tumor Cells*

  2008cites this paper
• TRAIL Resistance of Breast Cancer Cells Is Associated with Constitutive Endocytosis of Death Receptors 4 and 5

  2008cites this paper
• Present and Future Challenges

  2007cites this paper
• Selective targeting of death receptor 5 circumvents resistance of MG-63 osteosarcoma cells to TRAIL-induced apoptosis

  2007influential citation
• TRAIL in cancer therapy: present and future challenges

  2007cites this paper
• Enhancement of Sensitivity of Human Lung Cancer Cell Line to TRAIL and Gefitinib by IGF-1R Blockade

  2007cites this paper
• Neuroblastoma as a target for effector mechanisms of the immune system

  2007cites this paper
• On the TRAIL toward death receptor-based cancer therapeutics.

  2007cites this paper
• Valproic acid induces apoptosis in chronic lymphocytic leukemia cells through activation of the death receptor pathway and potentiates TRAIL response.

  2006cites this paper
• Decoy Receptor-2 Small Interfering RNA (siRNA) Strategy Employing Three Different siRNA Constructs in Combination Defeats Adenovirus-Transferred Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Resistance in Lung Cancer Cells

  2006cites this paper